Onkologie - spezialisierte Tumortherapie

Peritonealkarzinose - Bauchfellkarzinose - Bauchfellkrebs
chirurgische Onkologie - regionale Chemotherapie - Peritonektomie

Multimodality treatment of diffuse malignant pleural mesothelioma

February 2002 • Volume 29 • Number 1

Lambros S. Zellos [MEDLINE LOOKUP]
David J. Sugarbaker [MEDLINE LOOKUP]

Sections
  • Abstract
  • Clinical Presentation, Diagnostic Workup, and Staging
  • Single Modality Treatment
  • Multimodality Treatment
  • Conclusions
  • References
  • Publishing and Reprint Information

 

Diffuse malignant pleural mesothelioma (DMPM) is a challenging disease in all of its aspects, from presentation and diagnosis to staging and treatment. Single-modality therapy was the initial approach to this disease. It generally has not been effective in changing the natural history of DMPM. As a result, multimodality regimens involving surgery with radiation, chemotherapy, or immunotherapy delivered regionally or systemically have been evaluated. Randomized controlled studies comparing various strategies are lacking and, thus, the debate continues regarding the effectiveness of different treatment approaches.
Semin Oncol 29:41-50. Copyright © 2002 by W.B. Saunders Company.


WHILE DIFFUSE malignant pleural mesothelioma (DMPM) is still a rare disease, its annual incidence is believed to be increasing. Between 2,000 and 3,000 new cases of DMPM are expected each year.1 Many physicians encounter mesothelioma few times in their entire career, if at all. The difficulty in recognizing and diagnosing mesothelioma early in its course, along with a very short period from diagnosis to the patient's death, has resulted in a rather fatalistic approach to the disease among physicians. Single-modality therapy has failed overall to significantly change the natural history median survival of 4 to 12 months.2 While various aggressive multimodality regimens, which have implemented aggressive cytoreductive surgery followed by adjuvant therapy, have had success in prolonging the median survival, debate continues among surgeons regarding which cytoreductive surgery is the most appropriate. However, in mesothelioma, like any other disease, each treatment should be offered to the appropriate subset of patients. Unfortunately, the approach towards mesothelioma has been “one size fits all.” The lack of a universally accepted staging system has certainly contributed to this approach. Nevertheless, advances have been made in the treatment of DMPM, and the median survival has increased considerably for patients with early-stage disease treated with aggressive multimodality regimens.

Clinical presentation

The typical DMPM patient who presents for surgical evaluation is a male over the age of 55 (3:1 male-to-female ratio) with unilateral disease (95%). DMPM tends to be right-sided (60%).3 Patients usually report symptoms related to the presence of a pleural effusion, such as dyspnea, cough, chest pain that may be nonpleuritic in nature, and occasionally fever, night sweats, fatigue, and weight loss.3 Unrelenting local spread with invasion into the chest wall, the lung and its fissures, the mediastinal structures, and diaphragm are characteristic. The time from presentation to diagnosis can be as long as 2 to 3 months.

Diagnosis

A high index of suspicion is needed, especially in patients with exposure to asbestos. Options include thoracentesis, closed pleural biopsy, and video-assisted thoracic surgery (VATS). Cytologic examination has a low diagnostic yield (35% to 50%), and, similarly, closed pleural biopsy has a high false-negative rate.4>6 While repeated procedures and computed tomography (CT) guidance can increase the diagnostic yield of closed pleural biopsies, seeding of the needle tracts can occur, resulting in the eventual development of chest wall masses. When DMPM is suspected, it is appropriate to proceed directly to VATS. VATS can effectively drain a loculated effusion, and by providing adequate tissue samples for histology, immunohistochemistry, and electron microscopy7 (Table 1), a 90% or better diagnostic yield can be achieved.8


Table 1. Staining and microscopic profiles of malignant pleural mesotheliomas, adenocarcinomas, and localized fibrous tumors of the pleura
Marker MPM AC LFTP
Diastase-PAS + (50%)
Hyaluronic acid +++ +/–
Mucicarmine + (50%)
CD34 +(80%)
CEA +/– (10%) + (>75%)
Cytokeratins Diffuse cytoplasmic perinuclear Peripheral cytoplasmic or membrane-associated
EMA Membrane Diffuse, cytoplasmic
Leu-M1 (CD15) + (60–70%)  
Desmosomes/tonofilaments Abundant Few
Secretory granules, glycocalyceal bodies +  
Villi Long, thin, curved, branched (LDR > 15) Short, thick, straight, sparse (LDR < 10) Absent
Vimentin ++

Abbreviations: AC, adenocarcinoma; LDR, length-to-diameter ratio; CEA, carcinoembryonic antigen; EMA, epithelial membrane antigen; LFTP, localized fibrous tumors of the pleura; MPM, malignant pleural mesothelioma; PAS, periodic acid–Schiff.
Reprinted with permission.7

Because seeding of the VATS incision with tumor cells can also occur, the VATS incision should be placed along the site of future surgical incisions so that it can be clearly visible when it is excised or irradiated.

Staging

Staging is crucial in deciding the appropriate regimen for patients with DMPM. Because those with positive resection margins, N2 nodal disease, or advanced stage do not enjoy prolonged survival (especially with sarcomatous or mixed pathology), staging procedures should attempt to identify these patients.9 While all patients should undergo CT scans of the chest and abdomen, debate continues regarding the utility of magnetic resonance imaging (MRI). MRI can provide a better assessment than CT scan of apical and diaphragmatic regions, as well as chest wall involvement.10 Unnecessary thoracotomies can be avoided by better defining resectability. We currently require both CT and MRI scans of the chest and abdomen.

The role of positron emission tomography (PET) scan in staging DMPM was evaluated in 18 patients by Schneider et al.11 PET scan detected distant disease in two patients who had negative CT scans. PET scan was also more accurate in the assessment of mediastinal nodes. Benard et al assessed the standard uptake value (SUV) of lesions on PET scans as a predictor of survival. High SUV values (mean SUV, 6.6 v 3.2) were found to have a negative impact on survival, suggesting that tumor burden could be quantified.12

While PET scan can have quite low false-negative rates, its increased sensitivity does result in false-positive scans. The standard of staging remains cervical mediastinoscopy, which can accurately assess tumor involvement of N2 nodes with minimal discomfort to the patient. When CT scan is the principal staging method, a high number of patients undergoing exploratory surgery will be found to be technically unresectable or have advanced disease. Rusch and Venkatraman reported that of 131 patients staged with CT scan, 32 (24%) had technically unresectable disease and 46 (35%) had mediastinal nodal involvement.13

Echocardiogram is another useful test in the preoperative workup of patients. It can assess pericardial invasion by the tumor, determine cardiac function, and hence assist in determining the appropriate management.

Several mesothelioma staging systems have been proposed, but none are universally accepted. While a staging system should stratify survival and hence direct therapy, most staging systems have failed to so. Butchart et al introduced the first mesothelioma staging system in 1976 (Table 2).14


Table 2. The Butchart staging system
Stage Definition
I Tumor is confined to the capsule of the parietal pleura (ie, involves only the ipsilateral lung, pleura, pericardium, and/or diaphragm)
II Tumor invades the chest wall or mediastinal structures (eg, esophagus, heart, and/or contralateral pleura), or
  Tumor involves intrathoracic lymph nodes
III Tumor penetrates the diaphragm to involve peritoneum, or
  Tumor involves the contralateral pleura, or
  Tumor involves extrathoracic lymph nodes
IV Distant blood-borne metastases

Reprinted with permission.14

Although the Butchart system remains one of the most popular, it has not been validated. This system was based on only 29 patients and fails to stratify survival based on stage. Boutin et al showed that with Butchart's stage I, subsets of patients could have a median survival range of 7 to almost 33 months, depending on the degree of parietal pleural involvement.15 Overall, 70% of patients with Butchart stage I have a median survival between 5 and 14 months. Other proposed systems include the revised Brigham/Dana-Farber Cancer Institute (DFCI) (Table 3),9 the Union Internationale Contre Cancer (UICC), and the International Mesothelioma Interest Group (IMIG) (Table 4) staging systems.16,17
Table 3. Revised staging system proposed by Sugarbaker et al9
Stage Definition
I Disease completely resected within the capsule of the parietal pleura without adenopathy: ipsilateral pleura, lung, pericardium, diaphragm, or chest wall disease limited to previous biopsy sites
II All of stage I with positive resection margins and/or intrapleural adenopathy
III Local extension into the chest wall or mediastinum; into the heart or through the diaphragm or peritoneum; or with extrapleural lymph node involvement
IV Distant metastatic disease

NOTE. Patients with Butchart stage II and III disease14 are combined into stage III. Stage I represents patients with resectable disease and negative nodes. Stage II indicates resectable disease but positive nodes.
Reprinted with permission.9
Table 4. Staging system proposed by the International Mesothelioma Interest Group (IMIG)
Tumor (T) staging
  T1a Tumor limited to the ipsilateral parietal pleura, including the mediastinal and diaphragmatic pleura, without involvement of the visceral pleura
  T1b TIa + scattered foci of tumor involving the visceral pleura
  T2 Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features:
  • involvement of diaphragmatic muscle
  • confluent visceral pleural tumor (including the fissures) or extension of tumor from the visceral pleura into the underlying pulmonary parenchyma
  T3 Locally advanced but potentially resectable tumor. The tumor involves all of the ipsilateral pleural surfaces with at least one of the following features:
  • involvement of the endothoracic fascia
  • extension into the mediastinal fat
  • a solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall
  • non-transmural involvement of the pericardium
  T4 Locally advanced, technically unresectable tumor. The tumor involves all of the ipsilateral pleural surfaces with at least one of the following features:
  • diffuse extension or metastatic spread to the chest wall with or without rib destruction
  • direct trans-diaphragmatic extension to the peritoneum
  • direct extension to the contralateral pleura
  • direct extension to any mediastinal organ
  • direct extension to the spine
Lymph node (N) staging
  Nx Regional lymph nodes (LNs) cannot be assessed
  N0 No regional LN metastases
  N1 Involvement of ipsilateral bronchopulmonary or hilar LNs
  N2 Involvement of subcarinal or ipsilateral mediastinal LNs (including the internal mammary LNs)
  N3 Involvement of the contralateral mediastinal or internal mammary LNs or any supraclavicular LNs
Metastases (M) staging
  Mx Presence of distant metastases cannot be assessed
  M0 No distant metastases
  M1 Distant metastases present
Overall staging
  Stage I  
  1a T1a N0 M0
  1b T1b N0 M0
  Stage II T2 N0 M0
  Stage III Any T3 M0
    Any N1 M0
    Any N2 M0
  Stage IV Any T4
    Any N3
    Any M1

Reprinted with permission.16

The last two are tumor-nodal-metastasis (TNM)-based and use the nodal system identical to the one used for lung cancer. The IMIG system is the most recently proposed, but it is complicated and has not been validated.

The revised Brigham/DFCI system classifies patients according to positive resection margins, intrapleural (N1) and/or extrapleural nodal status (N2), and invasion beyond the pleural envelope.9 It was based on 183 patients who underwent extrapleural pneumonectomy and adjuvant chemoradiation. This system does stratify survival according to stage. Information on resection margins can only be obtained postoperatively, but preoperative MRI can increase the precision of preoperative clinical staging. Similarly, mediastinoscopy can assess N2 nodes. While there are limitations to mediastinoscopy in evaluating extrapleural nodes, selected use of mediastinoscopy could assist surgeons in determining benefits of aggressive cytoreduction in patients with borderline functional status or with borderline predicted postoperative FEV1. Because positive N2 nodes do not preclude extrapleural pneumonectomy (EPP), mediastinoscopy is not advocated in all patients with mesothelioma. The median survival durations of patients who have undergone EPP and adjuvant chemoradiation according to the revised Brigham/DFCI staging system were 25, 20, and 16 months for stages I, II, and III, respectively. The Brigham/DFCI is a simpler system compared to the other staging systems; however, validation in an independent patient population is pending.9

 

Radiation therapy

Unresected diffuse malignant pleural mesothelioma is difficult to treat with radiation alone. Unlike other tumors, mesothelioma is a diffuse process, and a much larger radiation field is required compared to other thoracic malignancies. Numerous vital structures limit the radiation dose that can be safely delivered (lung, 20 Gy; liver, 30 Gy; spinal cord, 45 Gy; heart, 45 Gy; and esophagus, 45 to 50 Gy).18 The Joint Center for Radiation Therapy in Boston conducted a review of mesothelioma patients treated with different doses of radiation using palliation as the endpoint. Only one of 23 patients who received less than 40 Gy achieved palliation, while four of six patients who were given more than 40 Gy had satisfactory palliation.19 The effect of radiation on survival was not assessed. In some patients, doses up to 60 Gy may be necessary, depending on tumor burden; this can produce significant complications, including radiation pneumonitis, myelitis, and hepatitis. Thus, it is not surprising that response rates to radiation as low as 3% have been reported.20

Radiation therapy can effectively prevent or decrease malignant seeding after thoracentesis, closed pleural biopsy, or VATS. Boutin et al randomized 40 patients to 21 Gy in three fractions to VATS sites 10 to 15 days after thoracoscopy. While 40% of patients who did not receive radiation therapy developed metastases at the VATS sites, none of the 20 patients who received radiation to VATS sites developed metastases at their incisions.21

Surgery

The three surgical procedures that have been used for the treatment or palliation of DMPM are pleurodesis, pleurectomy/decortication (P/D), and EPP. There have been no randomized studies comparing these three procedures. The retrospective studies use different staging systems and do not always group patients by stage.

VATS with pleurodesis is performed to palliate without cytoreduction. The effusion is effectively drained, and any loculations present can be disrupted. Four agents have been used to sclerose: tetracycline, doxycycline, bleomycin, and talc. Randomized trials of talc versus bleomycin, tetracycline versus bleomycin, and doxycycline versus bleomycin found the resulting inflammatory reaction and palliation to be equivalent with each agent.22>24 While pleurodesis increases the difficulty of future cytoreductive procedures, P/D or EPP can still be performed by experienced surgeons without prohibitive complication rates.

Proponents of this procedure suggest it should be the definitive treatment for mesothelioma because cytoreductive surgery (EPP or P/D) as a single modality has not resulted in significant prolongation of median survival and subject the patient to added morbidity and mortality. Additionally, they point to in vitro studies that have shown a 39% tumoricidal effect of talc on cell lines to propose that talc could be used as the sole treatment.25 However, large studies that have used talc pleurodesis as the sole surgical treatment have reported median survival similar to that of the natural history of the disease.26 This procedure may be appropriate for patients with multiple comorbidities that preclude aggressive surgery, however.

The cytoreductive procedures include P/D and EPP. While both are performed with curative intent, there is debate regarding which technique is most appropriate.

The visceral and parietal pleura, the pericardium, and the diaphragm can be removed during P/D. This procedure is not as technically demanding as EPP and because it does not remove the entire lung, it poses less physiologic strain on patients. It can be tolerated by patients whose functional status precludes EPP, and it can be performed by most centers without prohibitive mortality rates. Most series have reported mortality rates in the range of 1.5% to 5%.27 Proponents of P/D point to these benefits and also to the high mortality rates reported after EPP in older studies (30% mortality) and the failure of EPP to prolong survival as a single modality (10% 5-year survival).14

There are several disadvantages to P/D: mesothelioma can invade the lung fissures making complete resection difficult; postoperative radiation is limited due to the presence of the lung; and local recurrence occurs in the vast majority of the patients (80% in some studies).28 Additionally, large, modern studies have markedly reduced the operative mortality of EPP to less than 4%, making it a more attractive procedure for some patients with good functional status and an appropriate disease setting.9

EPP is a more aggressive procedure that involves en bloc resection of the parietal and visceral pleura with the enclosed lung, pericardium, ipsilateral diaphragm, and mediastinal nodes. It is a more effective cytoreductive procedure than P/D. In addition, with the lung removed, a higher amount of radiation can be delivered. EPP has a more pronounced physiologic impact on the patient. The obvious disadvantage of EPP is the greater physiologic reserve required of the patient and the higher incidence of postoperative morbidity and mortality than seen with P/D. Postoperative complication rates can vary widely between centers. The Butchart series of 29 patients14 reported a mortality rate of 30% after EPP. As experience with this procedure has grown, numerous series have reported lower mortality rates, but there are still modern series that report significant mortality rates. The largest series of EPP reported a mortality rate of 3.8%.9

Selection of the appropriate patient subset for EPP is crucial. This procedure should be done by a surgeon who has experience in the postoperative management of complications and in an institution with the support to manage these complicated patients. Potential complications of EPP include bronchial leaks, empyema, vocal cord paralysis, chylothorax, patch failure, and post-EPP constrictive physiology.

There has not been a randomized study that compares P/D to EPP as a single-modality treatment for DMPM. However, neither procedure as a single modality has resulted in significant prolongation of the median survival. It is within the setting of multimodality therapy that EPP has resulted in improved survival of patients with early-stage disease.

Chemotherapy

Chemotherapy regimens for mesothelioma are extensively reviewed in the articles by Drs Baas, Fizazi, and Kindler in this issue. It suffices to state that chemotherapy is not curative, and while there may be new regimens with promising activity, there are currently no data to indicate that chemotherapy as a single modality affects survival in this disease.29>31


Several multimodality approaches have been evaluated for the treatment of DMPM due to the failure of single modality therapy to affect survival. Cytoreductive surgery (P/D or EPP) has been incorporated with intrapleural or external-beam radiotherapy, intrapleural and/or systemic immunotherapy, and chemotherapy. Efforts have mainly focused on improving local control of this disease.

EPP and adjuvant chemoradiation

Brigham and Women's Hospital has the largest series evaluating multimodality treatment of DMPM.32,33 This protocol includes EPP followed by sequential chemotherapy and radiation. EPP was chosen for the protocol because it provides the maximum local cytoreduction. A standardized preoperative assessment protocol helps select only those patients who can tolerate EPP. Eligibility criteria include presence of potentially resectable disease, absence of significant systemic comorbidities (cardiac, renal, hepatic), and adequate functional status. Resectability is determined with CT scans, MRI, and echocardiograms. All three tests are obtained for each patient. These studies should demonstrate no chest wall invasion, no contralateral disease, no transdiaphragmatic involvement, and no mediastinal invasion.

Preoperative functional status is assessed with the Karnofsky performance score, pulmonary function tests, arterial blood gases (ABG), and echocardiograms. The Karnofsky performance score should be greater than 70. The ABGs should show PCO2 less than 45 mm Hg and PO2 greater than 65 mm Hg. The echocardiogram should demonstrate an ejection fraction greater than 45%. Adequate postoperative functional status is mainly determined with predicted postoperative FEV1 and quantitative ventilation-perfusion scans (V/Q). The predicted postoperative FEV1 should be greater than 1 L. For patients with borderline pulmonary function (preoperative FEV1 of 2 L), V/Q scans can predict postoperative FEV1 more accurately.9,34

EPP requires en-bloc resection of the parietal pleura, lung, pericardium, and diaphragm. The pericardial and diaphragmatic defects are reconstructed with patches (Gore-Tex, W.L. Gore, Flagstaff, AZ) to prevent cardiac or abdominal organ herniation. The postoperative care of EPP patients is similar to that of standard pneumonectomy. Pain control with epidural catheter placement is essential in order to reduce atelectasis and pulmonary dysfunction. Arterial lines, central venous lines, pulse oximeters, and monitoring in the intensive care unit are crucial to avoid significant intravascular volume changes. A high index of suspicion for deep vein thrombosis (DVT) is important because pulmonary embolus cannot be tolerated by these patients. DVT prophylaxis is done with subcutaneous heparin and pneumatic boots. Avoiding episodes of fluid overload and pulmonary edema is crucial. Fluid restriction (1 L/d) should be instituted during the first 3 to 5 days and a diuretic should be administered if indicated as early as postoperative day 0. Mediastinal shift can occur after pneumonectomy and results in tamponade or venous flow obstruction. Occasionally, fluid from the ipsilateral chest may need to be drained to decrease the mediastinal shift. Vocal cord paralysis can occur and a high index of suspicion and low threshold for endoscopy are essential to prevent aspiration. After a recovery period of 4 to 6 weeks, the patient is referred to a multidisciplinary program for adjuvant chemoradiation.

One hundred eighty-three patients underwent EPP between 1980 and 1997 at Brigham and Women's/DFCI. There were seven perioperative deaths, for a mortality rate of 3.8%. The 176 surviving patients underwent adjuvant treatment. Adjuvant chemoradiation is initiated after a recovery period of 4 to 6 weeks. Several adjuvant chemotherapy regimens have been evaluated at the DFCI over time. Patients treated prior to 1985 received doxorubicin and cyclophosphamide. Cisplatin was included in the regimen in 1985. In 1994, the regimen was revised to two cycles of carboplatin and paclitaxel, followed by radiation with concomitant weekly paclitaxel. The regimen concludes with two additional cycles of carboplatin and paclitaxel. More recently, chemotherapy has included gemcitabine with either cisplatin or carboplatin.

Radiation is delivered to the hemithorax at a dose of 30 Gy, while the mediastinum receives 40 Gy. If gross residual disease, positive microscopic margins or positive nodes are present, then a boost dose of 14 Gy is given. The total dose that can potentially be delivered is 54 Gy.9

The 176 patients achieved 2- and 5-year survival rates of 38% and 15%, respectively9 (Fig 1).

 

Fig. 1. Kaplan-Meier survival curve for all patients surviving surgery (n = 176) in the multimodality series from the Brigham and Women's Hospital. Reprinted with permission.9
multimortality1

A survival analysis determined the following to be significant prognostic variables: histologic subtype, lymph node involvement, resection margins, and invasion beyond the pleural envelope. These variables form the basis of the revised Brigham/DFCI staging system9

The subset of patients with epithelial histology and stage I disease (revised Brigham/DFCI staging system, ie, negative lymph nodes and negative margins) had a median survival of 51 months and 2- and 5-year survival rates of 68% and 46%, respectively. None of the patients with sarcomatous histology and positive N2 nodes or positive margins survived 5 years.9

The 176 patients were also staged according to the IMIG and Butchart staging systems. While the revised Brigham/DFCI system stratified patient survival by stage (P= .0011), the other two staging systems failed to do so (Butchart system. P= .09; IMIG system, P= .31). This aggressive trimodality approach and the revised Brigham/DFCI staging system identified the most appropriate subset of patients who should undergo such therapy: patients with epithelial histology, negative nodes, and completely resectable disease.9

The importance of accurate clinical staging cannot be overstated. Accurate determination of resectability with MRI is crucial. While PET scan has shown promise in staging mediastinal disease, mediastinoscopy remains the standard. Biopsy of mediastinal nodes can accurately stage patients and prevent operations in patients with nonepithelial histology when resectability is questionable.

A subset of these 183 patients (n = 49) who underwent trimodality therapy were reviewed to assess patterns of failure. Between 1987 and 1993, 49 patients with DMPM were evaluated. There were three perioperative deaths; therefore, 46 of 49 patients were eligible for analysis. The median follow-up was 18 months. Twenty-five (54%) patients had disease recurrence.35 Ipsilateral chest recurrence was seen in 35% of patients, abdominal recurrence in 26%, and contralateral chest recurrence in 17%.35 Despite this aggressive protocol, locoregional recurrence was still the predominant mode of failure. However, systemic failure was seen more frequently, suggesting that the multimodality therapy may have an impact in the natural history of this disease.

For patients who do not meet the inclusion criteria for EPP, cytoreduction is achieved with P/D. Patients receive similar adjuvant therapy except that the radiotherapy is focused on the wound to prevent chest wall metastasis due to seeding rather than on the entire hemithorax because the lung is still present.

P/D with brachytherapy and external-beam radiation

The Memorial Sloan-Kettering Cancer Center has evaluated a multimodality approach that incorporates intraoperative brachytherapy after P/D, followed by external-beam radiation.27 Between 1976 and 1988, 105 patients had 125I seeds or 192Ir implants placed in the ipsilateral hemithorax after P/D in areas with gross residual disease. A total external-beam radiation dose of 4,500 cGy was given to the ipsilateral hemithorax. Median survival was 12.5 months. One- and 2-year overall survival rates were 52% and 23%, respectively. Patients with early disease and epithelial tumors had a better survival. In the 27 patients with epithelial histology and minimal residual disease, median survival was 15 months, and 1- and 2-year survival rates were 68% and 35%, respectively. Despite cytoreduction and brachytherapy, 61% of patients had local recurrence.27

P/D or EPP with intrapleural and systemic chemotherapy

Intrapleural drug delivery can achieve increased local drug concentrations and prolonged drug exposure with less systemic toxicity; cytotoxicty is limited by tissue penetration of drug. The Memorial Sloan-Kettering Cancer Institute and the Cleveland Clinic have evaluated intrapleural chemotherapy immediately after cytoreduction followed by systemic chemotherapy.28,36 The Memorial Sloan-Kettering group used P/D with immediate intrapleural cisplatin and mitomycin C (100 mg/m2 and 8 mg/m2, respectively). Systemic chemotherapy with the same agents was initiated 3 to 5 weeks postoperatively. Thirty-six patients were enrolled, and 28 underwent P/D and intrapleural chemotherapy.28

There was one perioperative death (3.6%) and two episodes of grade 4 renal failure. Twenty-three of the 27 surviving patients received systemic chemotherapy. The 1- and 2-year survival rates for the 27 patients were 68% and 40%, respectively; the median survival was 17 months. Sixteen of 20 patients (80%) had locoregional recurrence.28

The Cleveland Clinic used a similar regimen in 19 patients with clinical stage I disease. Nine patients underwent P/D and 10 had EPP. The P/D patients received intrapleural cisplatin and mitomycin C immediately postprocedure, while the patients who underwent EPP received intrapleural cisplatin 1 to 2 weeks after the procedure. There was one perioperative death for a mortality rate of 5%. Fifteen patients received systemic, cisplatin-based chemotherapy, which was poorly tolerated and resulted in one death. Median survival was 13 months and the median disease-free survival was 11 months.36

A recently reported series by Juturi et al from the Cleveland Clinic investigated the role of intracavitary paclitaxel as a component of multimodality therapy.37 Twenty-two patients accrued since 1995 underwent EPP or P/D, intracavitary paclitaxel, then chemoradiation with intravenous paclitaxel. The toxicity of this regimen was considerable, including empyema, wound dehiscence, mucositis, neutropenia, neutropenic sepsis, and one toxic death. Median survival was 9 months. Locoregional metastases developed in 64% despite the aggressive multimodality regimen.

While median survival appears to have been prolonged in the Memorial Sloan-Kettering series of intrapleural and systemic chemotherapy following P/D, this was not replicated in the Cleveland Clinic series. Additionally, locoregional recurrence was not affected despite intracavitary chemotherapy.

P/D or EPP with hyperthermic, intrapleural, chemotherapeutic infusion

Hyperthermia has been shown to induce cell death. It also appears to improve the efficacy of chemotherapeutic agents. Stehlin pioneered its use for the treatment of melanoma, where the addition of hyperthermia markedly improved the efficacy of the chemotherapeutic agents.38 In theory, hyperthermia with intracavitary chemotherapy could improve the tumoricidal effects against DMPM. Few studies of intracavitary hyperthermic perfusion of cisplatin have been conducted. Matsuzaki and colleagues used hyperthermic cisplatin at 43°C to treat pleural implants or effusions in lung cancer patients.39 They observed high concentrations of cisplatin in the pleural cavity during perfusion. Ratto et al studied hyperthermic intrapleural perfusion in DMPM. Three patients underwent P/D and normothermic cisplatin, three patients underwent P/D and hyperthermic cisplatin, and four patients underwent EPP and hyperthermic perfusion. The cisplatin dose used was 100 mg/m2. There was higher systemic absorption of the cisplatin with P/D than EPP. Hyperthermic perfusion achieved higher local tissue concentrations of cisplatin than normothermic perfusion.40

The Brigham and Women's Hospital has completed a phase I, dose-escalating study to determine the maximum tolerated dose of cisplatin after EPP; the results have not yet been published. A similar phase I study for P/D is ongoing. Phase II trials are in development.

Photodynamic therapy after EPP or P/D

Photodynamic therapy (PDT) combines light with a photosensitizer that has selective uptake in malignant cells. A phase III study performed by Pass et al compared cytoreduction, postoperative cisplatin, interferon-2b, and tamoxifen with and without intraoperative PDT using photofrin.41 From 1993 to 1996, 63 patients were entered into this study; 15 patients could not achieve cytoreduction to less than 5 mm. Twenty-five patients received PDT and 23 patients did not. A total of 23 P/Ds and 25 EPPs were performed. The two groups of patients were comparable in terms of type of resection and stage. Although patients were selected based on localized disease preoperatively, 79% of patients were found to have stage III disease at surgery. There was no difference in median survival (14.4 v 14.1 months), major morbidity, nor sites of first recurrence between the two groups.41

Moskal et al reported the Roswell Park Cancer Institute experience of 40 patients with DMPM who underwent cytoreduction and intracavitary PDT. Twenty-four of 40 patients had advanced disease (stage III or IV). While median survival was 15 months for the 37 patients who survived postoperatively, patients with early disease (stage I and II, n = 13) had a median survival of 36 months; those with advanced disease had a median survival of 10 months.42

Second-generation photosensitizers are now under investigation.

Novel therapies

Newer therapies, such as chemoimmunotherapy, angiogenesis inhibitors, and vaccines, have not been evaluated in multimodality regimens to date. If these or other approaches begin to show promise in advanced disease, they may be incorporated into adjuvant multimodality regimens. The review by Nowak et al in this issue discusses these agents in detail.


DMPM remains a difficult disease to treat. Like any other malignancy, early diagnosis is essential. Treatment must be tailored according to stage and histologic subtype. Overall, there is a trend in these studies for improved survival in patients with early stage disease. Patients with advanced disease have not enjoyed this benefit with multimodality regimens. The Brigham/DFCI approach of EPP and adjuvant chemoradiation with a median survival of 51 months is the longest survival of any reported series. In its current form, intrapleural or systemic adjuvant chemoradiation after P/D, does not appear to affect locoregional recurrence.

While a high index of suspicion can be difficult to maintain for such a rare disease, when the diagnosis of DMPM is contemplated, referral to a center with extensive experience in the treatment of DMPM is important because diagnosis and staging can be performed expeditiously.7 Unless dramatic improvements are made with chemotherapy, immunotherapy or gene therapy, it is unlikely that single-modality therapy will become the treatment of choice for this disease. The diffuse nature of DMPM makes it difficult for radiotherapy alone to result in significant improvement in survival, although improvements in methodology could allow higher doses of radiation to be delivered. Further improvements in chemotherapy, PDT, hyperthermic intrapleural perfusion, gene therapy, and other novel agents in the setting of multimodality regimens that include aggressive cytoreduction with EPP could improve survival in the future.
Acknowledgment

The authors thank Mary S. Visciano for editorial assistance

1.
      Connelly RR, Spirtas R, Myers MH, et al: Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 78:1053-1060, 1987
MEDLINE

2.  Antman K, Shemin R, Ryan L, et al: Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985. J Clin Oncol 6:147-153, 1988
MEDLINE

3.  Sugarbaker DJ, Garcia JP, Richards WG, et al: Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients Ann Surg 224:288-294, 1996

4.  Renshaw AA, Dean BR, Antman KH, et al: The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 111:106-109, 1997
MEDLINE

5.  Dejmek A: Methods to improve the diagnostic accuracy of malignant mesothelioma. Respir Med 90:191-199, 1997

6.  Beauchamp HD, Kundra NK, Aranson R, et al: The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura. Chest 102:1110-1112, 1992
MEDLINE

7.  Ho L, Sugarbaker DJ, Skarin AT: Malignant pleural mesothelioma, in Ettinger DS (ed): Thoracic Oncology. Boston, MA, Kluwer, 2001, pp. 327-373

8.  Boutin C, Rey F: Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 72:389-393, 1993
MEDLINE

9.  Sugarbaker DJ, Flores R, Jacklitsch M, et al: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients J Thorac Cardiovasc Surg 117:54-65, 1999

10.  Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al: Malignant pleural mesothelioma: Value of CT and MR imaging in predicting resectability. AJR 159:961-966, 1992

11.  Schneider DB, Clary-Macy C, Challa S, et al: Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 120:128-133, 2000
MEDLINE
ABSTRACT
FULL TEXT

12.  Benard F, Sterman D, Smith RJ, et al: Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40:1241-1245, 1999
MEDLINE

13.  Rusch VW, Venkatraman E: The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 111:815-825, 1996
MEDLINE
ABSTRACT
FULL TEXT

14.  Butchart EG, Ashcroft T, Barnsley WC, et al: Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: Experience with 29 patients. Thorax 31:15-24, 1976
MEDLINE

15.  Boutin C, Rey F, Gouvernet J, et al: Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 72:394-404, 1993
MEDLINE

16.  Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122-1128, 1995
MEDLINE

17.  Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14:1-12, 1996
MEDLINE
CROSSREF

18.  Maasilta P: Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys 20:433-438, 1991
MEDLINE

19.  Ball DL, Druickhawk DG: The treatment of malignant mesothelioma of the pleura: Review of a 5-year experience with special reference to radiotherapy. J Clin Oncol 13:4-9, 1990

20.  Gordon W, Antman K, Breenberger J, et al: Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 8:19-25, 1982
MEDLINE

21.  Boutin C, Rey F, Viallat JR: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108:754-758, 1995
MEDLINE

22.  Noppen M, Degreve J, Mignolet M, et al: A prospective, randomised study comparing the efficacy of talc slurry and bleomycin in the treatment of malignant pleural effusions. Acta Clin Belg 52:258-262, 1997
MEDLINE

23.  Martinez-Moragon E, Aparicio J, Rogado MC, et al: Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 10:2380-2383, 1997
MEDLINE

24.  Patz EF Jr, McAdams HP, Erasmus JJ, et al: Sclerotherapy for malignant pleural effusions: A prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 113:1305-1311, 1998
MEDLINE

25.  Nasreen N, Mohammed KA, Dowling PA, et al : Talc induces apoptosis in human malignant mesothelioma cells in vitro. Am J Respir Crit Care Med 161:595-600, 2000
MEDLINE

26.  Canto A, Guijarro R, Arnau A, et al: Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions. Thorac Cardiovasc Surg 45:16-19, 1997
MEDLINE

27.  Rusch VW: Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9:367-372, 1997
MEDLINE

28.  Rusch V, Saltz L, Venkatraman E, et al: A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12:1156-1163, 1994
MEDLINE

29.  Ryan CW, Herndon J, Vogelzang NJ: A review of chemotherapy trials for malignant mesothelioma. Chest 113:66S-73S, 1998 (suppl)

30.  Taub RN, Antman KH: Chemotherapy for malignant mesothelioma. Semin Thorac Cardiovasc Surg 9:361-366, 1997
MEDLINE

31.  Byrne MJ, Davidson JA, Musk AW, et al: Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 17:25-30, 1999
MEDLINE

32.  Sugarbaker DJ, Heher EC, Lee TH, et al: Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 102:10-14, 1991
MEDLINE

33.  Sugarbaker DJ, Mentzer SJ, DeCamp M, et al: Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 103:377S-381S, 1993 (suppl)

34.  Grondin SC, Sugarbaker DJ: Malignant mesothelioma of the pleural space. Oncology (Huntingt) 13:919-926, 1999
MEDLINE

35.  Baldini EH, Recht A, Strauss GM, et al: Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63:334-338, 1997
MEDLINE

36.  Rice TW, Adelstein DJ, Kirby TJ, et al: Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 58:24-29, 1994
MEDLINE

37.  Juturi JV, Adelstein DJ, Rice TW, et al: Intracavitary paclitaxel in the multimodality management of malignant pleural mesothelioma. Proc Am Soc Clin Oncol 20:366a, 2001 (abstr)

38.  Stehlin JS Jr: Hyperthermic perfusion for melanoma of the extremities: Experience with 165 patients, 1967 to 1979. Ann NY Acad Sci 335:352-355, 1980
MEDLINE

39.  Matsuzaki Y, Shibata K, Yoshioka M, et al: Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion. Ann Thorac Surg 59:127-131, 1995
MEDLINE

40.  Ratto GB, Civalleri D, Esposito M, et al: Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: A feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 117:759-765, 1999
MEDLINE
ABSTRACT
FULL TEXT

41.  Pass HI, Temeck BK, Kranda K, et al: Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunotherapy for malignant pleural mesothelioma Ann Surg Oncol 48:628-633, 1997

42.  Moskal TL, Dougherty TJ, Urschel JD, et al: Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg 66:1128-1133, 1998
MEDLINE

 

  • From the Department of Surgery, Division of Thoracic Surgery, Brigham and Women's Hospital; Department of Surgical Services, Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA.
  • Address reprint requests to David J. Sugarbaker, MD, Division of Thoracic Surgery, Brigham and Women's Hospital, 75 Francis St, Boston MA 02115.
  • Copyright © 2002 by W.B. Saunders Company

  • 0093-7754/02/2901-0006$35.00/0
  • doi:10.1053/sonc.2002.30230

Sollten Sie Fragen zu Inhalten dieser Webseite haben oder als Betroffener weitere Informationen benötigen, können Sie gerne mit uns in Kontakt treten. Zur korrekten, unentgeltlichen Beantwortung Ihrer Anfragen werden alle aktuellen Unterlagen, wie Laborbefunde, OP-Berichte und CT- oder MR-Bilder benötigt.
Für die Übermittlung Ihrer Anfrage steht Ihnen das Kontaktformular zur Verfügung

Dr. med. Herwart Müller

Chefarzt der Abteilung für Allgemeinchirurgie in Wertheim
Rotkreuzklinik Wertheim
E-Mail: Herwart.Mueller@swmbrk.de
Sekretariat: Frau Anneliese Holzhäuser, Frau Birgit Rauer
E-Mail: anneliese.holzhaeuser@swmbrk.de
birgit.rauer@swmbrk.de
Telefon: 09342/303-5002
Fax:         09342/303-5001
Empfang: 09342/303-0
Rotkreuzklinik Wertheim gGmbH, Rotkreuzstr. 2
97877 Wertheim

Rotkreuzklinik Wertheim gGmbH

Abteilung für Allgemeinchirurgie
Rotkreuzstr. 2
97877 Wertheim / Bayern
Telefon:
+49 9342 / 303-5002

Sprechstunde

Zur Vorstellung in der Sprechstunde werden alle aktuellen Unterlagen, wie Laborbefunde, OP-Berichte und CT- oder MR-Bilder benötigt